Summary
This document presents a summary of the 2025 European Association of Urology guidelines for muscle-invasive and metastatic bladder cancer, developed through systematic literature appraisal of Medline, EMBASE, and Cochrane databases. The guidelines prioritise thorough diagnosis, multidisciplinary treatment planning, and shared decision-making with patients. Notable updates include new recommendations on FGFR3 alterations for patient selection, revised radiotherapy protocols, organ-preserving techniques, lymph node dissection extent, hospital volume considerations, and salvage cystectomy management.
UK applicability
These EAU guidelines are directly applicable to UK urological practice, as the National Institute for Health and Care Excellence (NICE) often aligns recommendations with major European guideline bodies. UK hospital systems may require assessment against current NHS commissioning standards and capacity for multidisciplinary team coordination, particularly regarding radical cystectomy and specialist radiotherapy services.
Key measures
Clinical practice recommendations; treatment efficacy; patient outcomes; diagnostic protocols; follow-up protocols
Outcomes reported
The guidelines summarise evidence-based recommendations for diagnosis, treatment, and follow-up of patients with muscle-invasive and metastatic bladder cancer, with emphasis on multidisciplinary approaches and shared decision-making.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.